O. Shibata et al., Contractile and phosphatidylinositol responses of rat trachea to anti-cholinesterase drugs, CAN J ANAES, 45(12), 1998, pp. 1190-1195
Citations number
17
Categorie Soggetti
Aneshtesia & Intensive Care","Medical Research Diagnosis & Treatment
Journal title
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE
Purpose: Some anticholinesterases (anti-ChE) such as neostigmine and pyrido
stigmine but not edrophonium, stimulate phosphatidylinositol (PI) response.
Although a direct relationship was suggested between the increase in PI re
sponse and airway smooth muscle contraction, there are no data regarding th
e effects of anti-ChE drugs on airway smooth muscle. Thus, we examined the
contractile properties and PI responses produced by anti-ChE drugs.
Methods: Contractile response. Rat tracheal ring was suspended between two
stainless hooks in Krebs-Henseleit (K-H) solution, (I)Carbachol (CCh), anti
-ChE drugs (neostigmine, pyridostigmine, edrophonium) or DMPP (a selective
ganglionic nicotinic agonist) were added to induce active contraction. (2)
The effects of 4-diphenylacetoxy-N-methyl-piperidine methobromide (4-DAMP),
an M-3 muscarinic receptor antagonist, on neostigmine- or pyridostigmine-i
nduced contraction of rat tracheal ring were examined. (3) Tetrodotoxin (TT
X) was tested on the anti-ChE drugs-induced responses; PI response. The tra
cheal slices were incubated in K-H solution containing LiCl and (3)[H]myo-i
nositol in the presence of neostigmine or pyridostigmine with or without 4-
DAMP, an M-3 muscarinic receptor antagonist, (3)[H]inositol monophosphate (
IP,) formed was counted with a liquid scintillation counter
Results: Carbachol (0.1 mu M), neostigmine (1 mu M), pyridostigmine (10 mu
M) but not edrophonium or DMPP caused tracheal ring contraction. 4-DAMP but
not tetrodotoxin, inhibited neostigmine and pyridostigmine-induced contrac
tion. Neostigmine- or pyridostigmine-induced IF, accumulation was inhibited
by 4-DAMP,
Conclusions: The data suggest that anti-ChE drugs activate the M-3 receptor
s at the tracheal effector site.